3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
26
Prostatic Neoplasms
15
Carcinoma, Non-Small-Cell Lung
10
Sarcoma
9
Lung Neoplasms
6
Uterine Cervical Neoplasms
5
Endometrial Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Neoplasms
3
Liposarcoma, Myxoid
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Carcinoma In Situ
3
Urogenital Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma, Synovial
2
Radiation Injuries
2
Neurofibrosarcoma
2
Neoplasm Metastasis
2
Melanoma
2
Lymphatic Metastasis
2
Liposarcoma
2
Leiomyosarcoma
2
Histiocytoma, Malignant Fibrous
2
Fibrosarcoma
2
Cholangiocarcinoma
2
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Nivolumab
2
Gemcitabine
2
Cisplatin
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
tislelizumab
1
relatlimab
1
enzalutamide
1
enfortumab vedotin
1
durvalumab
1
Water
1
Urinary Diversion
1
Standard of Care
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Multiparametric Magnetic Resonance Imaging
1
Immunonutrition Diet
1
Immune Checkpoint Inhibitors
1
Gels
1
Fluorouracil
1
Docetaxel
1
Cystoscopy
1
Cystectomy
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urinary Bladder Diseases
×
Radiation Dose Hypofractionation
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled